Anti-EDG2/LPA-1 (Lysophosphatidic Acid Receptor 1) Rabbit Monoclonal Antibody for WB, ELISA - Q92633

Core Product Specifications and Parameters

Biological Background: EDG2/LPA-1 Function and Localization

• LPAR1 encodes a G protein-coupled receptor that binds lysophosphatidic acid (LPA), a bioactive lipid mediator involved in diverse cellular responses. Related references: PMID:19306925 PMID:25025571 PMID:26091040

• LPA signaling through LPAR1 activates multiple heterotrimeric G proteins (Gi/Go, G12/13, Gq), leading to inhibition of adenylyl cyclase, decreased cAMP, and increased cytoplasmic Ca²⁺ levels. Related references: PMID:26091040 PMID:19656035 PMID:19733258

• Downstream effectors include RALA-mediated phospholipase C activation, MAP kinase cascades, and Rho/RAC1-dependent cytoskeletal reorganization, promoting actin stress fiber formation and lamellipodia. Related references: PMID:19306925 PMID:26091040

• LPAR1 plays a critical role in cell migration, chemotaxis, and wound healing, with demonstrated involvement in fibrotic lung disease and stem cell motility. Related references: PMID:18066075 PMID:19656035 PMID:19733258

• The receptor also regulates developmental processes, including normal skeleton and brain development, osteoblast differentiation, and adult neurogenesis.

• Subcellularly, LPAR1 localizes to the plasma membrane and endosomes, consistent with dynamic receptor trafficking.

• The protein is subject to glycosylation, disulfide bond formation, and phosphorylation, which modulate its signaling and membrane expression.

• LPAR1 is broadly expressed in adult tissues (brain, heart, colon, prostate, ovary, etc.) but shows low expression in liver, lung, and peripheral blood leukocytes. Related references: PMID:9070858

Experimental Guidance and Technical Tips

• Given the immunogen design (N-terminal peptide, aa 1–100), the antibody is expected to recognize an epitope in the extracellular N-terminus of LPAR1; verify specificity using relevant controls.
• For Western blot, LPAR1 is a multi-pass membrane protein with a predicted molecular weight of ~41 kDa; inclusion of mild detergents in lysis buffer may be necessary to solubilize the receptor.
• In ELISA applications, consider using the immunogen peptide as a positive control to assess antibody binding.
• Due to the GPCR nature, post-translational modifications such as glycosylation may cause band shifts; deglycosylation treatment can be used to confirm target identity.
• Validate antibody performance in the appropriate species (human) and cell line expressing LPAR1; cross-reactivity with other species has not been determined.
• LPAR1 is known to internalize upon LPA stimulation; for immunofluorescence or functional studies, appropriate stimulation conditions may be required.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a dedicated B2B platform that empowers diagnostic manufacturers, research laboratories, and IVD developers with reliable access to a wide range of raw materials. From validated antibody pairs and optimized monoclonal antibodies to bulk ancillary reagents and rare target sourcing, we support projects spanning receptor biology, signal transduction, and cell migration. Contact us to secure consistent supply of anti-EDG2/LPA-1 antibodies and related reagents for your assay development pipeline.